Receptor Binding Domain Based HIV Vaccines

This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding d...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huan, Bi, Wenwen, Wang, Qian, Lu, Lu, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312573/
https://www.ncbi.nlm.nih.gov/pubmed/25667925
http://dx.doi.org/10.1155/2015/594109
_version_ 1782355134886445056
author Liu, Huan
Bi, Wenwen
Wang, Qian
Lu, Lu
Jiang, Shibo
author_facet Liu, Huan
Bi, Wenwen
Wang, Qian
Lu, Lu
Jiang, Shibo
author_sort Liu, Huan
collection PubMed
description This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding domain of gp120 as a target for developing AIDS vaccines. And we recommend some measures that could induce efficiently and produce cross-reactive neutralizing antibodies with high binding affinity. Those measures may offer a new way of the research and development of the potent and broad AIDS vaccines.
format Online
Article
Text
id pubmed-4312573
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43125732015-02-09 Receptor Binding Domain Based HIV Vaccines Liu, Huan Bi, Wenwen Wang, Qian Lu, Lu Jiang, Shibo Biomed Res Int Review Article This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding domain of gp120 as a target for developing AIDS vaccines. And we recommend some measures that could induce efficiently and produce cross-reactive neutralizing antibodies with high binding affinity. Those measures may offer a new way of the research and development of the potent and broad AIDS vaccines. Hindawi Publishing Corporation 2015 2015-01-15 /pmc/articles/PMC4312573/ /pubmed/25667925 http://dx.doi.org/10.1155/2015/594109 Text en Copyright © 2015 Huan Liu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Liu, Huan
Bi, Wenwen
Wang, Qian
Lu, Lu
Jiang, Shibo
Receptor Binding Domain Based HIV Vaccines
title Receptor Binding Domain Based HIV Vaccines
title_full Receptor Binding Domain Based HIV Vaccines
title_fullStr Receptor Binding Domain Based HIV Vaccines
title_full_unstemmed Receptor Binding Domain Based HIV Vaccines
title_short Receptor Binding Domain Based HIV Vaccines
title_sort receptor binding domain based hiv vaccines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312573/
https://www.ncbi.nlm.nih.gov/pubmed/25667925
http://dx.doi.org/10.1155/2015/594109
work_keys_str_mv AT liuhuan receptorbindingdomainbasedhivvaccines
AT biwenwen receptorbindingdomainbasedhivvaccines
AT wangqian receptorbindingdomainbasedhivvaccines
AT lulu receptorbindingdomainbasedhivvaccines
AT jiangshibo receptorbindingdomainbasedhivvaccines

Ejemplares similares